Melinta Therapeutics’ Post

Our amazing REMEDi4ALL colleagues from Syreon Research Institute are asking for your help!!!! Zsuzsanna Petykó, Dalma Hosszú, Zoltán Kaló 📣 Help REMEDi4ALL shape the policy environment for #DrugREPURPOSING by filling in the following survey! 💊 One of our goals in REMEDi4ALL is to 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐩𝐨𝐥𝐢𝐜𝐲 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 to ensure that more repurposed medicines can reach patients who need them. Understanding the hurdles that stand in the way of Drug Repurposing is critical to unleashing its full potential. We have identified and validated numerous policy barriers and we now need now to prioritise them and and focus on the most relevant ones. And this is were we need YOUR HELP! 💡 By participating in our online survey, you can rate the impact and actionability of various policy barriers to drug repurposing. Your feedback will inform our project activities and outputs and ultimately contribute to improving the lives of patients across Europe. 📝 𝐓𝐡𝐞 𝐬𝐮𝐫𝐯𝐞𝐲 𝐝𝐞𝐚𝐝𝐥𝐢𝐧𝐞 is the 𝟏𝟕𝐭𝐡 𝐨𝐟 𝐉𝐮𝐥𝐲. To start the survey, please click on this link:👉 https://lnkd.in/dHXbEZeq 𝐓𝐡𝐚𝐧𝐤 𝐲𝐨𝐮 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐯𝐚𝐥𝐮𝐚𝐛𝐥𝐞 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧! 🙏 EURORDIS-Rare Diseases Europe, Julian Isla, Tomasz Grybek....

The Venous Clinical Severity Score (rVCSS) is a key market in assessing CVI. A 3 Point Improvement represents evidence of a clinically meaningful benefit. https://bit.ly/48sIquX #VenousDisease #ChronicVenousInsufficiency #ChronicVenousDisease.

Your favorite anti-drug/ anti-science federal agency, Drug Endorcement Agency, has moved to place DOI and DOC, two research chemicals with no demonstrated history of risk of abuse and significant value to researchers, into Schedule I of the Controlled Substances Act. And they did so over the holidays, to avoid scrutiny from the industry that’s trying to bring psychedelic healing to the masses. They already tried to pull this in 2022 but withdrew their proposal in response to criticism from scientists and researchers and lawyers who are paying attention. Below is a link to comment on this proposed rule: https://lnkd.in/gT7qtcKG Let them know what you think. After all, even though they have forgotten, DEA works for you.

We recently announced positive initial 6-month topline efficacy data related VenoValve. Learn more here: https://bit.ly/43gGlBb #VenousDisease #ChronicVenousInsufficiency #ChronicVenousDisease

The Future of Blood Pressure Monitoring is Here Introducing LiveOne: the world’s first FDA-cleared, wrist-worn, cuff-free blood pressure monitor by LiveMetric! Say goodbye to uncomfortable cuffs and hello to continuous, real-time monitoring. Learn more about LiveOne: https://livemetric.com/ #DigitalHealth #Innovation #BloodPressureMonitoring #RemotePatientMonitoring

Resistance to colistin, a last-resort antibiotic therapy against multi-drug-resistant Gram-negative bacteria has emerged in Enterobacteriaceae species. The One Health Trust and collaborators traced the history of colistin resistance and analyzed the impact of regulatory policies on colistin use on the prevalence of resistant E. coli using a One Health approach. Find the article, “Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance” published in the International Journal of Antimicrobial Agents here: https://lnkd.in/dA_MecP4 #AntibioticResistance #OneHealth #Colistin

Verified Clinical Trials ™ is a global cross-sponsor research subject database registry that detects and prevents duplicate subjects and other important protocol violations immediately at the time of screening. The protections follow the subject for the entire duration of the clinical trial. Saves time and money for all stakeholders. VCT will reduce the placebo response and improve research subject safety. Help prevent your clinical trial from failure. Visit https://lnkd.in/etwhixy to learn more #duplicatesubjects #professionalresearchsubjects

Verified Clinical Trials ™ is a global cross-sponsor research subject database registry that detects and prevents duplicate subjects and other important protocol violations immediately at the time of screening. The protections follow the subject for the entire duration of the clinical trial. Saves time and money for all stakeholders. VCT will reduce the placebo response and improve research subject safety. Help prevent your clinical trial from failure. Visit https://lnkd.in/eRK5k36 to learn more #duplicatesubjects #professionalresearchsubjects

Verified Clinical Trials ™ is a global cross-sponsor research subject database registry that detects and prevents duplicate subjects and other important protocol violations immediately at the time of screening. The protections follow the subject for the entire duration of the clinical trial. Saves time and money for all stakeholders. VCT will reduce the placebo response and improve research subject safety. Help prevent your clinical trial from failure. Visit https://lnkd.in/eRK5k36 to learn more #duplicatesubjects #professionalresearchsubjects

𝐄𝐯𝐞𝐫 𝐰𝐨𝐧𝐝𝐞𝐫𝐞𝐝 𝐰𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐚𝐣𝐨𝐫 𝐜𝐚𝐮𝐬𝐞 𝐨𝐟 𝐓𝐫𝐢𝐚𝐥 𝐃𝐞𝐥𝐚𝐲𝐬?  It turns out that 70% of these delays are due to unexpected mid-study changes, which can be costly. Although these changes are often inevitable, Clinion can significantly reduce downtime by allowing you to review and deploy updates from testing to live studies with a button click. This gives you more time to focus on research and less time dealing with data hurdles. Want to learn more about how Clinion can add value to your research?  Request a demo today! https://lnkd.in/gF5G-xQv #ClinicalResearch #ClinicalTrials #ClinicalDataManagement #CDM #ClinicalResearchAssociate #CRA #DataManagement #ClinicalInnovation #ClinicalTrialManagement #ClinicalStudy #ClinicalStudyUpdates #ClinicalTrialEfficiency #DidYouKnow